In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

CRISPR, Vertex partner in $3.6bn CRISPR-Cas9 gene editing collaboration; later expanded to other disease areas

Executive Summary

CRISPR Therapeutics is lending its CRISPR-Cas9 gene editing technology to Vertex Pharmaceuticals Inc. as part of a four-year research collaboration aimed at discovering treatments to address the underlying genetic defects that cause or contribute to certain diseases, including cystic fibrosis and sickle cell disease.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register